Secondary dyslipidemia: its treatments and association with atherosclerosis

被引:37
|
作者
Yanai, Hidekatsu [1 ]
Yoshida, Hiroshi [2 ]
机构
[1] Kohnodai Hosp, Dept Diabet Endocrinol & Metab, Natl Ctr Global Hlth & Med, 1-7-1 Kohnodai, Chiba 2728516, Japan
[2] Jikei Univ, Dept Lab Med, Kashiwa Hosp, Chiba, Japan
来源
GLOBAL HEALTH & MEDICINE | 2021年 / 3卷 / 01期
关键词
hypothyroidism; low-density lipoprotein; nephrotic syndrome; triglyceride;
D O I
10.35772/ghm.2020.01078
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Dyslipidemia is classified into primary and secondary types. Primary dyslipidemia is basically inherited and caused by single or multiple gene mutations that result in either overproduction or defective clearance of triglycerides and cholesterol. Secondary dyslipidemia is caused by unhealthy lifestyle factors and acquired medical conditions, including underlying diseases and applied drugs. Secondary dyslipidemia accounts for approximately 30-40% of all dyslipidemia. Secondary dyslipidemia should be treated by finding and addressing its causative diseases or drugs. For example, treatment of secondary dyslipidemia, such as hyperlipidemia due to hypothyroidism, by using statin without controlling hypothyroidism, may lead to myopathy and serious adverse events such as rhabdomyolysis. Differential diagnosis of secondary dyslipidemia is very important for safe and effective treatment. Here, we describe an overview about diseases and drugs that interfere with lipid metabolism leading to secondary dyslipidemia. Further, we show the association of each secondary dyslipidemia with atherosclerosis and the treatments for such dyslipidemia.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 50 条
  • [41] Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study
    Zahra Jamali
    Mojgan Noroozi Karimabad
    Parvin Khalili
    Tabandeh Sadeghi
    Ahmadreza Sayadi
    Faegheh Mohammadakbari Rostamabadi
    Carlo La Vecchia
    Ali Esmaeili-Nadimi
    Scientific Reports, 12
  • [42] Association of Biomarkers of Inflammation with Dyslipidemia and Its Components among Mongolians in China
    Tang, Lingyan
    Peng, Hao
    Xu, Tian
    Wang, Aili
    Wang, Guiyan
    Tong, Weijun
    Zhang, Yonghong
    PLOS ONE, 2014, 9 (02):
  • [43] Body composition changes and its association with dyslipidemia in patients receiving hemodialysis
    Samanta, Priyadarsini
    Bhattacharyya, Debdattaa
    Panigrahi, Ansuman
    Mishra, Soumya
    Mishra, Jayanti
    Senapati, Laxman Kumar
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2021, 10
  • [44] Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure
    Tokgozoglu, Lale
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2009, 37 : 11 - 16
  • [45] SECONDARY HEMOCHROMATOSIS - ITS ASSOCIATION WITH ANEMIA
    KENT, G
    POPPER, H
    ARCHIVES OF PATHOLOGY, 1960, 70 (05): : 623 - 639
  • [46] PREVALENCE OF DYSLIPIDEMIA AND ITS ASSOCIATION WITH CLINICOPATHOLOGIC FEATURES IN IGA NEPHROPATHY PATIENTS
    Qiu, Y.
    Rong, R.
    Ye, H.
    Wen, Q.
    Hong, L.
    Yang, Q.
    Yu, X.
    NEPHROLOGY, 2016, 21 : 229 - 229
  • [47] Prevalence of dyslipidemia and its association with insomnia in a community based population in China
    Zhan, Yiqiang
    Zhang, Fen
    Lu, Leihong
    Wang, Jinsong
    Sun, Yihong
    Ding, Rongjing
    Hu, Dayi
    Yu, Jinming
    BMC PUBLIC HEALTH, 2014, 14
  • [48] Analysis of the prevalence of dyslipidemia in individuals with HIV and its association with antiretroviral therapy
    de Limas, Talita Gabriela
    Pinto, Gustavo de Araujo
    Marcato, Liz Miriane
    Coelho, Daniel Reszel
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2014, 47 (05) : 547 - 551
  • [49] Dyslipidemia Secondary to Hypothyroidism and Cholestasis
    Saavedra, Ana
    Rodrigues, Elisabete
    Carvalho, Davide
    ACTA MEDICA PORTUGUESA, 2020, 33 (03): : 204 - 207
  • [50] Potential Secondary Metabolites from Marine Sponge Aaptos aaptos for Atherosclerosis and Vibriosis Treatments
    Mohamad, Habsah
    Rosmiati
    Muhammad, Tengku Sifzizul Tengku
    Andriani, Yosie
    Bakar, Kamariah
    Ismail, Noraznawati
    Saidin, Jasnizat
    Latip, Jalifah
    Musa, Najiah
    Parenrengi, Andi
    NATURAL PRODUCT COMMUNICATIONS, 2017, 12 (08) : 1227 - 1230